Allworth Financial’s Dianthus Therapeutics DNTH Stock Holding History

Allworth Financial’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.7K	Buy	192 +170	+773%	+$14.8K	﹤0.01%	3253
2026 Q1	$1.85K	Buy	22 +14	+175%	+$811	﹤0.01%	4374
2025 Q4	$330	Sell	8 -1	-11%	-$39	﹤0.01%	4619
2025 Q3	$355	Buy	9 +1	+13%	+$26	﹤0.01%	4517
2025 Q2	$150	Sell	8 -19	-70%	-$356	﹤0.01%	4355
2025 Q1	$574	Buy	+27	New	+$595	﹤0.01%	3643
2023 Q3	–	Sell	-23	Closed	-$285	–	3463
2023 Q2	$285	Hold	23	–	–	﹤0.01%	3031
2023 Q1	$299	Buy	23 +3	+15%	+$33	﹤0.01%	2942
2022 Q4	$128	Hold	20	–	–	﹤0.01%	2891
2022 Q3	$0	Buy	+20	New	+$548	﹤0.01%	2758

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Allworth Financial's DNTH Position: Q2 2026 in Review

Allworth Financial increased its Dianthus Therapeutics (DNTH) stake by 773% in Q2 2026, buying an estimated $14.8K and bringing the position to 192 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3253.

Allworth Financial first reported a position in DNTH in Q3 2022 and has held it in 10 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Allworth Financial held 192 shares of Dianthus Therapeutics worth $18.7K as of Q2 2026.
Allworth Financial bought 170 Dianthus Therapeutics shares in Q2 2026, an estimated $14.8K.
Dianthus Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3253 holding.
Allworth Financial first reported a position in Dianthus Therapeutics in Q3 2022 and has held it in 10 quarters since.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.